Intralenticular Ozurdex® – One Year Later

Regan, Kathleen A.; Blake, Charles Richard; Lukowski, Zachary; Iyer, Siva S R

doi:10.1159/000485318

Cited by 13 publications

(16 citation statements)

References 12 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…ere are some conflicting studies that reported no cataract progression even after accidental intralenticular Ozurdex implant administration [24,25]. In addition, many authors have revealed a resolution of the ME with an intralenticular implant [24,[26][27][28][29].…”

Section: Discussionmentioning

confidence: 99%

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

Nicula

Nicula²,

Rednik³

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

Purpose. The purpose of the study was to assess the efficacy of intravitreal dexamethasone implant (IDI: Ozurdex®) injection in eyes with macular edema due to retinal vein occlusion. Material and Method. A retrospective, nonrandomized study was conducted in patients with macular edema (ME) due to retinal vein occlusion (RVO) who undertook intravitreal Ozurdex® as first-line treatment. We performed a complete ocular exam including macular OCT. Results. The mean BCVA (logMar) improved from 0.420.42 ± 0.23 logMar at baseline to 0.21 ± 0.23 logMar at 48 weeks in the BRVO group and from 0.72 ± 0.16 logMar at baseline to 0.31 ± 0.23 logMar at 48 weeks in the CRVO group. In both groups, CFT values decreased significantly compared to baseline (p<0.0001 at each timepoint). Reinjection for recurrent macular edema after 18 weeks was indicated in five eyes (41.67%) in the BRVO group and in six eyes (25%) in the CRVO group. Cataract developed in two eyes (16.67%) in the BRVO group and in one eye (4.17%) in the CRVO group. The IOP was higher than 25 mmHg in two cases in the BRVO group (16.66%) and in three cases (8.33%) in the CRVO group. Conclusion. Ozurdex® injected intravitreally significantly improved the mean CFT and BCVA in eyes with macular edema due to retinal vein occlusion.

show abstract

Section: Discussionmentioning

confidence: 99%

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

Nicula

Nicula²,

Rednik³

et al. 2020

Journal of Ophthalmology

View full text Add to dashboard Cite

show abstract

“…Abnormal position of the implant does not affect the efficacy of the implant, as has been demonstrated in cases of intralenticular placement of the implant even with a cataract formation 1 3. Anterior chamber migration is more sinister as it may potentially lead to corneal decompensation 5.…”

Section: Discussionmentioning

confidence: 91%

“…Management of complication from cases, arising out of intralenticular placement of Ozurdex with or without cataract formation has been described 1–3. Spontaneous migration, of an Ozurdex implant into the anterior chamber in the presence of anterior chamber implant has been described.…”

Section: Discussionmentioning

confidence: 99%

Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant

Sherman

Raman

2018

BMJ Case Rep

View full text Add to dashboard Cite

Ozurdex (Allergan, Irvine, California, USA) is a biodegradable sustained release intravitreal implant containing 0.7 mg dexamethasone in a solid polymer drug delivery system. In the UK, it is approved for use in patients with macular oedema secondary to retinal vein occlusion, diabetic maculopathy and non-infectious uveitis. Although the implant is meant to be injected into the vitreous cavity, it can be inadvertently injected into the crystalline lens. This can also migrate into the anterior chamber, under altered anatomical conditions of the anterior segment. We report a case of incompletely penetrated dexamethasone implant, in a patient undergoing treatment for macular oedema secondary to retinal vein occlusion. The partially penetrated implant was managed conservatively with a good outcome.

show abstract

“…Accelerated cataract development has been reported in some intralenticular Ozurdex implant administration cases [4–6], while other cases had increased IOP [8] or both these complications together [9, 10]. Poornachandra et al [11] and Clemente-Tomás et al [3] have reported no acceleration of cataract progression.…”

Section: Discussionmentioning

confidence: 99%

“…However, there have also been increasing reports of accidental injection of Ozurdex into the crystalline lens [3–13]. Some authors feel expectant waiting is better [3, 4, 7, 10, 11] while others suggest immediate phacoemulsification (PE) for the cataract [5, 6, 13].…”

Section: Introductionmentioning

confidence: 99%

Accidental Intralenticular Injection of Ozurdex® for Branch Retinal Vein Occlusion: Intact Posterior Capsule and Resolution of Macular Edema

Kurt

Durukan²,

Küçükevcilioğlu

2019

Case Reports in Ophthalmological Medicine

View full text Add to dashboard Cite

Purpose. We present a case of accidental intralenticular injection of Ozurdex implant in a patient with macular edema secondary to branch retinal vein occlusion. Method. A case report. Results. Intravitreal dexamethasone implant injection had been performed for macular edema due to left superior temporal vein branch occlusion to the left eye of a 78-year-old male patient. The slit-lamp examination 85 days later revealed that the dexamethasone implant was intralenticular. The best-corrected visual acuity (BCVA) was 0.16 on the Snellen chart. Cataract surgery was decided on for the cataract as there was no anterior chamber inflammation, the intraocular pressure (IOP) was normal, and the macular edema had resolved. Uneventful phacoemulsification within the bag intraocular lens placement was performed. Conclusions. Accidental intralenticular Ozurdex injection is an extremely rare complication. The surgeon must decide whether to continue to observe or intervene immediately when such a complication is encountered. Cataract surgery can be planned if the macular edema has resolved and a cataract has developed. It is important to evaluate the posterior capsule with ultrasound biomicroscopy and Scheimpflug imaging before the cataract surgery to ensure a safe surgical procedure.

show abstract

Intralenticular Ozurdex® – One Year Later

Cited by 13 publications

References 12 publications

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

Morphological and Functional Outcomes after Intravitreal Dexamethasone Injection for Macular Edema in Patients with Central Vein Occlusion at 48-Week Follow-Up

Incomplete scleral penetration of dexamethasone (Ozurdex) intravitreal implant

Accidental Intralenticular Injection of Ozurdex® for Branch Retinal Vein Occlusion: Intact Posterior Capsule and Resolution of Macular Edema

Contact Info

Product

Resources

About